Seroatlas · Human Serome Atlas

SLC2A13

Proton myo-inositol cotransporter

Also known as: HMIT, MYCT_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q96QE2
Gene
SLC2A13
Ensembl
ENSG00000151229
Chromosome
12
Canonical length
648 aa
Protein class
Metabolic proteins, Predicted membrane proteins, Transporters
Subcellular location
Nuclear membrane

OverviewNCBI Gene

Enables ATPase binding activity; myo-inositol:proton symporter activity; and protease binding activity. Involved in myo-inositol transport and positive regulation of amyloid-beta formation. Located in cell body; cell projection; and plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

648 residues, UniProt reviewed canonical sequence.

>Q96QE2|SLC2A13
     1  MSRKASENVE YTLRSLSSLM GERRRKQPEP DAASAAGECS LLAAAESSTS LQSAGAGGGG
    61  VGDLERAARR QFQQDETPAF VYVVAVFSAL GGFLFGYDTG VVSGAMLLLK RQLSLDALWQ
   121  ELLVSSTVGA AAVSALAGGA LNGVFGRRAA ILLASALFTA GSAVLAAANN KETLLAGRLV
   181  VGLGIGIASM TVPVYIAEVS PPNLRGRLVT INTLFITGGQ FFASVVDGAF SYLQKDGWRY
   241  MLGLAAVPAV IQFFGFLFLP ESPRWLIQKG QTQKARRILS QMRGNQTIDE EYDSIKNNIE
   301  EEEKEVGSAG PVICRMLSYP PTRRALIVGC GLQMFQQLSG INTIMYYSAT ILQMSGVEDD
   361  RLAIWLASVT AFTNFIFTLV GVWLVEKVGR RKLTFGSLAG TTVALIILAL GFVLSAQVSP
   421  RITFKPIAPS GQNATCTRYS YCNECMLDPD CGFCYKMNKS TVIDSSCVPV NKASTNEAAW
   481  GRCENETKFK TEDIFWAYNF CPTPYSWTAL LGLILYLVFF APGMGPMPWT VNSEIYPLWA
   541  RSTGNACSSG INWIFNVLVS LTFLHTAEYL TYYGAFFLYA GFAAVGLLFI YGCLPETKGK
   601  KLEEIESLFD NRLCTCGTSD SDEGRYIEYI RVKGSNYHLS DNDASDVE

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLC2A13 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
12
Mean surface accessibility (rSASA)
0.3
Highest tissue expression
27 nTPM

Expression across tissuesHPA

Tissue

  • cerebral cortex: 27 nTPM
  • parathyroid gland: 21 nTPM
  • cervix: 12 nTPM
  • kidney: 10 nTPM
  • basal ganglia: 9.6 nTPM
  • hypothalamus: 8.9 nTPM

Single-cell type

  • choroid plexus epithelial cells: 905 nCPM
  • retinal horizontal cells: 561 nCPM
  • brain inhibitory neurons: 506 nCPM
  • other brain neurons: 469 nCPM
  • lactotrophs: 443 nCPM
  • oligodendrocyte progenitor cells: 411 nCPM

Immune cell

  • naive B-cell: 0.5 nTPM
  • eosinophil: 0.2 nTPM
  • memory CD8 T-cell: 0.1 nTPM
  • neutrophil: 0.1 nTPM
  • NK-cell: 0.1 nTPM
  • basophil: 0 nTPM

Brain region

  • choroid plexus: 57 nTPM
  • cerebral cortex: 52 nTPM
  • midbrain: 48 nTPM
  • hypothalamus: 45 nTPM
  • thalamus: 43 nTPM
  • basal ganglia: 42 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SLC2A13.

Disease | ImmuneIEDB

Conditions an epitope on SLC2A13 was assayed in.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.38
gnomAD pLI
0.83
gnomAD missense Z
1.48
DepMap mean gene effect
-0.09
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLC2A13 as an antibody target. Whether an autoantibody or antibody against SLC2A13 could matter depends on whether native SLC2A13 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLC2A13 is annotated at the cell surface, where native SLC2A13 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SLC2A13 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SLC2A13. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...